Etanercept及其在血液病中的应用
摘要
大量研究表明肿瘤坏死因子在多种炎性疾病及血液病的发病机制中扮演一定的角色。因此，作为一种肿瘤坏死因子拮抗剂Etanercept，为这些疾病，尤其是一些难治复发血液病的治疗提供了一种新的选择。本文就Etanereept的药理作用、安全性及其在多种血液病中的应用作一介绍。
出处
《国际输血及血液学杂志》
CAS
2007年第4期358-361,共4页
International Journal of Blood Transfusion and Hematology
参考文献16
-
1Tsimberidou AM, Waddelow T, Kantarjian HM, et al. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR: Fc; Enbrel) in patients with refractory multiple myeloma., increase in plasma TNF alpha levels during treatment. Leuk Res, 2003,27 (5) : 375-380.
-
2Tsimberidou AM, Thomas D, O'Brien D, et al. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol, 2002, 50 ( 3 ):237- 242.
-
3Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis faetor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and funetion simultaneously as both TNF carriers and TNF antagonists. J Immunol, 1993, 151 (3): 1548- 1561.
-
4Tsimberidou AM, Giles FJ. TNF-α targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther, 2002,2 (3) : 277- 286.
-
5Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.Arthritis Rheum, 2001,44(5):1149-1154.
-
6Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation,2001,103(8):1044-1047.
-
7Lebwohl M, Blum R, Berkowitz E, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol, 2005,141(7) :861-864.
-
8Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-α, Fas, and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol, 1998,103(1):176-188.
-
9Deeg HJ, Gotlib J, Beckham C, et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia,2002,16(2):162-164.
-
10Deeg HJ ,Jiang PY,Holmberg LA,et al. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res,2004,28(11):1177-1180.
-
1trial Krueger G.G.,Langley R.G.,Finlay A.Y.,焦婷.采用依那西普治疗获得改善的银屑病患者的临床结局自述——一项Ⅲ期随机试验结果[J].世界核心医学期刊文摘（皮肤病学分册）,2006,2(3):43-44.
-
2孙琳,郎需和,王兆芬,潘秀霞,王增良,王晓东.关节腔注射肿瘤坏死因子拮抗剂联合甲氨蝶呤治疗类风湿关节炎疗效观察[J].中国实用医药,2014,9(18):166-167. 被引量：3
-
3张徐明,刘群,吴頔,于乐,梅寒颖.甲氨蝶呤与依那西普联用对类风湿关节炎患者的临床疗效及安全性分析[J].抗感染药学,2015,12(6):996-998. 被引量：6
-
4郭小清,王爱霞.肿瘤坏死因子拮抗剂的临床应用前景[J].中华内科杂志,1997,36(1):64-65. 被引量：1
-
5阿达木单抗可用于治疗成人类风湿性关节炎[J].世界临床药物,2003,24(7):387-387.
-
6赵延恕,罗小岚,周宏年,赵水平,王志坚.福辛普利对老年慢性心力衰竭患者血清可溶性肿瘤坏死因子受体的影响[J].中国现代医学杂志,2003,13(22):134-136.
-
7白岚,姜云飞,牛杰志,张振书,张亚历.可溶性肿瘤坏死因子受体的治疗作用[J].国外医学（免疫学分册）,1999,22(5):291-294. 被引量：5
-
8吴波,江超.他克莫司治疗儿童中重度特应性皮炎的临床研究[J].中国临床药理学杂志,2014,30(9):770-772. 被引量：11
-
9苏国海,颜淑红,朱兴雷,丁福生.可溶性肿瘤坏死因子受体与心力衰竭关系的研究[J].山东医科大学学报,2000,38(2):166-167.
-
10奚涛.可溶性肿瘤坏死因子受体的纯化及其性质研究[J].药物生物技术,2000,7(1):28-31.
